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Emery-Dreifuss muscular dystrophy (EMD) is a condition characterized by the clinical triad of early-onset con-
tractures, progressive weakness in humeroperoneal muscles, and cardiomyopathywith conduction block. The disease
was described for the first time as an X-linked muscular dystrophy, but autosomal dominant and autosomal recessive
forms were reported. The genes for X-linked EMD and autosomal dominant EMD (AD-EMD) were identified. We
report here that heterozygote mutations in LMNA, the gene for AD-EMD, may cause diverse phenotypes ranging
from typical EMD to no phenotypic effect. Our results show that LMNA mutations are also responsible for the
recessive form of the disease. Our results give further support to the notion that different genetic forms of EMD
have a common pathophysiological background. The distribution of the mutations in AD-EMD patients (in the
tail and in the 2A rod domain) suggests that unique interactions between lamin A/C and other nuclear components
exist that have an important role in cardiac and skeletal muscle function.
Emery-Dreifuss muscular dystrophy (EMD) (MIM
310300 and 310200) is a condition characterized by the
clinical triad of early-onset contractures, progressive
weakness in humeroperoneal muscles, and cardiomy-
opathy with conduction block (Emery 1989; Toniolo et
al. 1998). It is important to recognize EMD as separate
disorder, because the disease is associated with life-
threatening cardiomyopathy that can be managed by
insertion of cardiac pacemakers. The disease was de-
scribed for the first time as an X-linked disorder (Emery
and Dreifuss 1966), and members of many families who
showed X-linked recessive inheritance were later de-
scribed. Autosomal dominant (Fenichel et al. 1982;
Miller et al. 1985; Yates 1997) and autosomal recessive
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forms (Takamoto et al. 1984; Taylor et al. 1998) of EMD
were also reported. As the clinical symptoms are very
similar, it has been suggested that the different genetic
forms may have a common pathophysiological back-
ground.
The genes for X-linked (X-EMD) and autosomal-
dominant EMD (AD-EMD) have been identified (Bione
et al. 1994; Bonne et al. 1999). The X-EMD gene en-
codes emerin, a ubiquitous protein localized, in most cell
types, to the inner nuclear membrane (Nagano et al.
1996; Cartegni et al. 1997; Manilal et al. 1998; Morris
and Manilal 1999). Emerin most likely interacts with
the nuclear lamina, a mesh of intermediate filaments (the
lamins) that constitute the nuclear cytoskeleton (Stuur-
man et al. 1998). AD-EMD is caused by mutations in
the gene LMNA, which encodes two lamins, A and C,
by differential maturation of the 3′ end of the mRNA
(Lin and Worman 1993). The finding that lamin A/C
and emerin mutations are responsible for clinically sim-
ilar disorders shows that in skeletal muscle and heart,
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Table 1
Patients Analyzed
Patient
Age
(years) Sex Inheritance Diagnosis
Cardiac
Involvement Mutation Exon Effect of Mutation Reference
MG 40 M Sporadic X-EMD or CMD None C644T 4 H222Y )
FG 17 M Sporadic X-EMD Pacemaker at age
16 years
G746A 4 R249Q )
CE-30 33a M Sporadic X-EMD AV block G746A 4 R249Q )
Rb 31 M Sporadic X-EMD Pacemaker at 31
years  DCM
G746A 4 R249Q )
II-1 ) M Familial LGMD1A  EMD DCM 960delT 6 FS from R321 Brodsky et al. (2000)
PD 16 M Sporadic EMD None G1007A 6 R336Q )
DPC 49a M Sporadic EMD Pacemaker at 41
years  RCM
C1357T 7 R453W )
MS 39 M Sporadic X-EMD or RSS Pacemaker at 31
years
C1357T 7 R453W Voit et al. (1988)
LC 42 M Sporadic X-EMD or RSS Tachyarrhythmia
and AV block
C1357T 7 R453W )
21a-III/5 21 M Sporadic X-EMD None C1357T 7 R453W )
AH 31 F Familial AD-EMD Pacemaker at age
28 years
T1406C 8 I469T Orstavik et al. (1990)
TB 58 M Sporadic X-EMD Pacemaker at age
43 years
G1580C 9 R527P )
GC 23 M Sporadic X-EMD or RSS Tachyarrhythmia
and AV block
C1583A 9 T528K )
NOTE.—CMD = congenital muscular dystrophy; AV = atrioventricular; DCM = dilated cardiomyopathy; F = female; M = male; RSS = rigid
spine syndrome; RCM = restrictive cardiomyopathy.
a Age at death.
interactions between nuclear membrane components are
critical for skeletal and cardiac muscle function, and loss
of integrity of the nuclear envelope is an underlying
cause of muscular dystrophy.
From the study of mutations in the LMNA gene in
selected AD-EMD pedigrees, it was apparent that the
clinical manifestations in individuals affected by AD-
EMD could be quite different from those with the typical
EMD phenotype (Bonne et al. 1999).We have, therefore,
investigated additional cases of AD-EMD, to extend the
number of known mutations and to look for phenotype-
genotype correlations. Most of the patients we studied
were males who had been referred for diagnosis of X-
EMD. Few were familial cases; the majority were spo-
radic (table 1). Only some of the patients had a classical
EMD phenotype (patients TB, FG, AH, and CE-30);
others were diagnosed as atypical EMD (DPC and PD)
or as affected by congenital muscular dystrophy, limb
girdle muscular dystrophy, or rigid-spine syndrome. The
cardiac involvement was also heterogeneous. Both
bradyarrhythmias (which frequently required pace-
maker implantation) and tachyarrhythmias were ob-
served in patients (table 1). In some patients, dilated
cardiomyopathy (DCM) or restrictive cardiomyopathy
(RCM) were reported (table 1). Patient Rb was diag-
nosed at age 31 years after severe heart block. Echo-
cardiography showed mild DCM. Patient II-1 is a mem-
ber of a family that will be described in detail elsewhere
(Brodsky et al. 2000); the patient presented with severe
DCM and variable skeletal muscle involvement. Patient
DPC, in whom a pacemaker had been implanted when
he was 41 years old, died of sudden cardiac arrest at
age 49 years. Finally, some patients (for example, MG,
at age 40 years) did not show evidence of cardiac
involvement.
In all patients, mutations in the X-linked emerin gene
were excluded by sequence analysis (Bione et al. 1995).
A set of 27 primers was used to PCR-amplify all exons
and exon-intron junctions of the LMNA gene, as de-
scribed elsewhere (Bonne et al. 1999). Because we found
recurrent mutations, the strategy for mutation detection
was to use direct sequencing of PCR products for exons
6–9 and to analyze the rest of the gene by single strand
conformation polymorphism (SSCP). PCR products of
exons showing band shifts were sequenced. Mutations
in the LMNA gene were found in 13 patients of the 25
we analyzed (table 1). Only one patient, II-1, had a 1-
bp deletion (960delT); all other mutations were non-
conservative modifications of highly conserved amino
acid residues (data not shown). In most instances, the
mutations also caused a change in the amino acid charge
that could disrupt the highly organized structure of the
lamins (Stuurman et al. 1998). Absence of the mutations
among 100 chromosomes of individuals not presenting
the phenotype was determined by restriction-enzyme di-
gestion or by denaturing high-performance liquid chro-
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Figure 1 Chromatograms of the portions of the sequencing gels showing the presence of mutations below the pedigrees of the families
of patient MG (a) and of patient PD (b). The position of the mutation is indicated (arrow). Sequences were performed and analyzed as described
by Bione et al. (1995).
matography (DHPLC) (Oefner and Underhill 1995,
1998).
Our analysis showed that, in addition to AD-EMD,
the LMNA gene is responsible for AR-EMD and for a
semidominant form of the disorder. Both SSCP and se-
quence analysis (fig. 1a) demonstrated that patient MG
(table 1) was a homozygote for the mutation C664T,
causing the amino acid change H222Y in a histidine
conserved from human to chicken and in lamin B1 (data
not shown). Sequence analysis of the rest of the LMNA
gene in the patient demonstrated that C664T was the
only mutation. His parents, who were first cousins, were
heterozygotes. The mutation was not found among 200
chromosomes of individuals unaffected by EMD that we
analyzed by DHPLC.
Patient MG presented with a very severe form of mus-
cular dystrophy that had been diagnosed either as an
atypical EMD or as congenital muscular dystrophy. The
patient experienced difficulties when he started walking
at age 14 mo; at age 5 years, he could not stand because
of contractures. At age 40 years, he presented severe and
diffuse muscle wasting and was confined to a wheelchair.
His intelligence was normal; careful cardiological ex-
amination showed that he did not have cardiac prob-
lems. His parents were unaffected. They had had recent
clinical and cardiological examinations, including elec-
trocardiograms, echocardiographs, and Holter electro-
cardiograms. None of them presented skeletal muscle or
cardiac alterations.
DNA from family members of sporadic patients was
analyzed (when it was available) to determine whether
some of the relatives, especially the very young ones,
might be carriers of the mutation or might be mildly or
not yet affected. Patient PD carried a R366Q amino acid
change (table 1). Analysis of the patient’s family mem-
bers showed that the mutation was present in the pro-
band’s grandmother and mother and in one of the sisters
(fig. 1b). After we found the mutation, we carefully ex-
amined these family members for the presence of clinical
symptoms. At the time of the study, the proband’s grand-
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Figure 2 Schematic representation of the structural organization of lamin A/C and of the position of the mutations found. The four
mutations described by Bonne et al. (1999) are Q6X, R453W, R527P (2X), and L530P. When mutations were found repeatedly, the number
of patients is indicated in brackets. a-helical regions are shown (slash marks), as are conserved sequences in 1A and 2B (blackened squares).
CBR = chromatin-binding region; NLS = nuclear localization signal.
mother was 80 years old and healthy, as was the pro-
band’s mother at age 40 years. The proband’s sister had
slightly elevated creatine kinase levels and no other
symptoms at age 12 years. All the exons of patient PD
were examined by direct sequencing, but no other mu-
tation was found. To exclude the possibility that the
mutation was a polymorphism, 200 chromosomes of
unaffected individuals were analyzed byDHPLC.We did
not find the mutation in the unaffected population.
Patient PD had a very mild disorder: he showed early
Achilles-tendon contractures and very mild, nonpro-
gressive pelvic-girdle muscle weakness. Lumbar spine ri-
gidity and retraction of the elbows started at age 13
years. At age 17 years, neurological examination showed
moderate rigid spine, bilateral elbow retraction and
equinism, and mild pelvic-girdle weakness. Cardiologic
examination indicated that the proband’s heart was nor-
mal. The appearance of a mild phenotype in the third
generation, in the absence of a second mutation in
LMNA, suggested the existence of a modifier gene or
genes that may have been responsible for the hetero-
geneity of the phenotype (Toniolo et al. 1998; Bonne et
al. 1999).
In summary, the mutation analysis of the LMNA gene
in patients affected with EMD showed that mutations
in LMNA caused a range of diverse phenotypes and a
larger clinical variability than that observed for X-EMD.
We definitively demonstrated the existence of AR-EMD,
and we showed that, in the same pedigree, a mutation
may have different penetrance and behave either as dom-
inant or as recessive. Our results indicate that the LMNA
gene should be studied, in the absence of a typical EMD
phenotype, in all patients presenting early contractures
of humeroperoneal muscle, a rigid spine, or both. Dif-
ferences caused by penetrance of the mutations may
complicate the diagnosis andmust be taken into account.
We analyzed a small group of patients referred for
diagnosis of X-EMD. Mutations in LMNA suggest that
patients affected with AD-EMD are underdiagnosed and
that their number is likely higher than predicted from
family studies. The number of isolated cases in our sam-
ple (11 of 13) also suggest that the frequency of new
mutations may be higher for AD-EMD than X-EMD
(Yates 1997).
Among the dominant mutations described in this
study and in Bonne et al. (1999), the majority were
amino acid changes that could result in a dominant neg-
ative effect. It is significant that recurrent changes were
observed in AD-EMD patients: 11 of 16 (68%) domi-
nant mutations causing AD-EMD were localized to the
central region of the tail domain, and three of the re-
maining five patients carried the same mutation in the
2A rod domain (fig. 2). Fatkin et al. (1999) recently
described mutations in LMNA in patients affected with
DCM and with conduction system disorders but who
did not present with contractures or skeletal myopathy:
four mutations were in rod domain 1 and one in the tail
of lamin C. Lamins are involved in multiple interactions
with themselves (Stuurman et al. 1998), with proteins
of the nucleus of the nuclear envelope (Foisner and Ger-
ace 1993; Martin et al. 1995; Furukawa et al. 1997;
Worman et al. 1988), and with chromatin (Hoger et al.
1991; Glass et al. 1993; Taniura et al. 1995). The dif-
ferent distribution along lamin A/C of the mutations in
AD-EMD and DCM patients suggests that the tail do-
main and the two rod domains of lamin A/C participate
in different interactions in skeletal or cardiac muscle.
This interpretation can also explain the finding of a mu-
tation in patients affected with Dunnigan-type familial
partial lipodystrophy, a disorder of adipocytes associ-
ated with insulin resistance and diabetes but not with
muscular or cardiac alterations (Cao and Hegele 2000).
This very unexpected finding suggests that the interac-
tions of lamin A/C may be diverse in different cell types
and that specific mutations may modify some of the
interactions, eventually causing tissue or cell-type-spe-
cific alterations of the nuclear envelope.
How does a lamin defect cause EMD?Mostmutations
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affecting emerin are null (Morris and Manilal 1999),
and lack of emerin seems to be the cause of X-EMD. It
has been suggested that haploinsufficiency or a dominant
negative effect caused by mutations in lamin A/C mod-
ifies the nuclear lamina and the nuclear envelope and
causes, either directly or indirectly, misplacement or
modifications of the distribution of emerin (Toniolo and
Minetti 1999). Alternatively, a third component, in ad-
dition to emerin and lamin A/C, may exist, and its cel-
lular distribution may be altered by lack of emerin and
by mutations in lamin A/C. From this point of view, the
recently published study of mice lacking lamin A (Sul-
livan et al. 1999) is of great interest. Soon after birth,
the Lmna / mice develop severe muscular dystrophy;
their phenotype is associated with ultrastructural per-
turbations of the nuclear envelope and mislocalization
of emerin. Another nuclear envelope protein, LAP2,
which is known to interact with chromatin and B-type
lamins (Foisner and Gerace 1993) but not with lamin
A/C, was found at the nuclear envelope. Study of specific
Lmna mutations in the mouse model in the heterozygotic
and homozygotic state may help clarify the role of and
the interactions of lamin A/C in different affected tissues.
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